DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
AngioDynamics (ANGO) Settles Patent Litigations With BD
by Zacks Equity Research
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes
by Zacks Equity Research
Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution
by Zacks Equity Research
Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
by Zacks Equity Research
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
by Zacks Equity Research
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
by Zacks Equity Research
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval
by Zacks Equity Research
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume
by Zacks Equity Research
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Boston Scientific (BSX) and Scivita Medical Expand Partnership
by Zacks Equity Research
Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
by Zacks Equity Research
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
by Zacks Equity Research
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
by Zacks Equity Research
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.